Purpose: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? Treatment with T-DM1 and placebo or T-DM1 and tucatinib, for up to 14 cycles, unless the breast cancer returns or the side effects become too severe. If the breast cancer returns while on the study, the treatment will be changed. After completion of T-DM1 and/or placebo, or T-DM1 and tucatinib, the study doctor will continue to follow the patients condition with clinic visits every 6 months for 10 years and watch for side effects and for signs of breast cancer returning.

If you have high risk prostate cancer, you may be able to participate in a research study to find out decreasing or increasing your radiation and hormonal therapy has an effect on your cancer.

Have you been diagnosed with high-risk early triple-negative breast cancer (TNBC) without mutations in the BRCA1 or BRCA2 gene? If you still have evidence of TNBC in your breast or lymph node tissue after receiving treatment and surgery, you may qualify for this clinical research study. This study will test an experimental drug combination to find out which treatment is better at delaying the return of cancer.

This is a clinical research study for people with Stage 4 lung cancer or lung cancer that has returned after treatment. In this study, we want to learn if treatment with two study drugs (ramucirumab and pembrolizumab) works better than usual treatment.

Do you have a history of ER+/HER2- breast cancer? Have you completed surgery and been on hormonal therapy for at least 2 years? If you have an increased risk of your cancer returning in the future, you may be able to take part in this clinical trial to help us learn if a new oral "SERD" therapy will further reduce the chance of recurrence.